

Seirbhís Aisíoca Príomhchúraim
Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 XKF3
Guthán: 01 8647100



Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3
Tel: 01- 8647100

Marian Harkin, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

1st March, 2021

PQ: 8414/21

To ask the Minister for Health the reason ozempic insulin pen is not covered under the drugs repayment scheme; if he will consider including this medication on the long-term illness scheme; and if he will make a statement on the matter. -Marian Harkin

Dear Deputy Harkin,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 8414/21), which you submitted to the Minister for Health for response.

Medicines are added to the formal Reimbursement List following detailed assessments which include assessment of the clinical evidence, the economic evidence and the budget impact of a decision to reimburse specific indications of a medicine. The Primary Care Reimbursement Service is required to reimburse in line with approved decisions of the HSE and the HSE is required to formally assess each medicines and each specific use of such medicines before reimbursing them.

Semaglutide marketed as Ozempic[®] was approved by the HSE for addition to the Reimbursement List for the treatment of Diabetes in 2018. Diabetes is one of the Long Term Illness (LTI) conditions for which eligible LTI persons can access their medicines to treat their Diabetes free of charge. Semaglutide has not been approved for reimbursement for any other indication.

Controls are in place within the Primary Care Reimbursement Service scheme management systems (and are put in place and updated as required) on claiming processes to ensure that only HSE approved indications are reimbursed across a range of medicines. Controls are currently in place in relation to both Liraglutide (Victoza[®]) and Semaglutide (Ozempic[®]) to restrict reimbursement support to the HSE approved indication of Diabetes. Persons with Diabetes are eligible for the Long Term Illness Scheme and may access Liraglutide and Semaglutide via that eligibility. Therefore, neither medicine is made available on the Drugs Payment Scheme

Yours sincerely,

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service